Ontogeny of Drug Transporters

Felmlee, Melanie A.; Zhang, Qing

doi:10.1002/9781119739883.ch19

Cited by 1 publication

(1 citation statement)

References 94 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In vivo, the establishment of the functional and complete BTB occurs after 15-18 days postpartum in mice (Hogarth, 2015;Moroi et al, 1998;Willems et al, 2010;Xiong et al, 2018) and 15-21 days postpartum in rats (Bergmann and Dierichs, 1983;Russell et al, 1989;Toyama et al, 2001). This is important because data collected using immature SCs may not be representative of the findings collected in adult animals due to ontogenetic changes in transporter expression (Brouwer et al, 2015;Cheung et al, 2019;Felmlee and Zhang, 2022;van Groen et al, 2021). These transporter expression changes may be, in part, associated with changing hormone or immunomodulatory factor levels as animals mature and spermatogenesis begins.…”

Section: Rodent Sertoli Cell Modelsmentioning

confidence: 99%

In Vitro and In Vivo Models for Drug Transport Across the Blood-Testis Barrier

2023

View full text Add to dashboard Cite

The blood-testis barrier (BTB) is a selectively permeable membrane barrier formed by adjacent Sertoli cells (SCs) in the seminiferous tubules of the testes that develops intercellular junctional complexes to protect developing germ cells from external pressures. However, due to this inherent defense mechanism, the seminiferous tubule lumen can act as a pharmacological sanctuary site for latent viruses (e.g., Ebola, Zika) and cancers (e.g., leukemia). Therefore, it is critical to identify and evaluate BTB carrier-mediated drug delivery pathways to successfully treat these viruses and cancers. Many drugs are unable to effectively cross cell membranes without assistance from carrier proteins like transporters because they are large, polar, and often carry a charge at physiological pH. SCs express transporters that selectively permit endogenous compounds, such as carnitine or nucleosides, across the BTB to support normal physiological activity, although reproductive toxicants can also use these pathways, thereby circumventing the BTB. Certain xenobiotics, including select cancer therapeutics, antivirals, contraceptives, and environmental toxicants, are known to accumulate within the male genital tract and cause testicular toxicity; however, the transport pathways by which these compounds circumvent the BTB are largely unknown. Consequently, there is a need to identify the clinically relevant BTB transport pathways in in vitro and in vivo BTB models that recapitulate human pharmacokinetics and pharmacodynamics for these xenobiotics. This review summarizes the various in vitro and in vivo models of the BTB reported in the literature and highlights the strengths and weaknesses of certain models for drug disposition studies.

show abstract